Identification of genes related to heart failure using global gene expression profiling of human failing myocardium.
暂无分享,去创建一个
Hiroshi Asanuma | Atsushi Nakano | Yulin Liao | Osamu Seguchi | Tadashi Isomura | Kyung-Duk Min | Toshiaki Otsuka | Masafumi Kitakaze | N. Mochizuki | H. Asanuma | S. Sanada | Y. Liao | S. Takashima | M. Asakura | M. Kitakaze | A. Nakano | T. Minamino | T. Otsuka | Masanori Asakura | Kenji Nakamaru | Hidetoshi Okazaki | Tomoko Takahashi | Kazunori Fujimoto | Shin Ito | Ayako Takahashi | Satoru Yamazaki | Tetsuo Minamino | Shoji Sanada | Yosuke Ando | Hidehiko Furukawa | Seiji Takashima | Naoki Mochizuki | H. Furukawa | Yosuke Ando | O. Seguchi | S. Yamazaki | K. Fujimoto | S. Ito | T. Isomura | Hidetoshi Okazaki | Kyung-duk Min | K. Nakamaru | Ayako Takahashi | Tomoko Takahashi
[1] J. Cohn,et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. , 1996, The New England journal of medicine.
[2] W. Koch,et al. Differential gene expression and genomic patient stratification following left ventricular assist device support. , 2003, Journal of the American College of Cardiology.
[3] J. Reagan,et al. Kynurenic Acid as a Ligand for Orphan G Protein-coupled Receptor GPR35* , 2006, Journal of Biological Chemistry.
[4] K. Kawakami,et al. A cardiac myosin light chain kinase regulates sarcomere assembly in the vertebrate heart. , 2007, The Journal of clinical investigation.
[5] Hiroshi Asanuma,et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy , 2002, Nature Medicine.
[6] K. Shinjo,et al. 5-Nitro-2-(3-Phenylpropylamino)benzoic Acid Is a GPR35 Agonist , 2008, Pharmacology.
[7] M. Asakura,et al. Global gene expression profiling in the failing myocardium. , 2009, Circulation journal : official journal of the Japanese Circulation Society.
[8] J. Rysä,et al. Distinct Upregulation of Extracellular Matrix Genes in Transition From Hypertrophy to Hypertensive Heart Failure , 2005, Hypertension.
[9] Paul D Allen,et al. Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. , 2002, The American journal of pathology.
[10] L. Hawthorn,et al. Decreased SLIM1 Expression and Increased Gelsolin Expression in Failing Human Hearts Measured by High-Density Oligonucleotide Arrays , 2000, Circulation.
[11] Ulrich Mansmann,et al. Identification of a common gene expression signature in dilated cardiomyopathy across independent microarray studies. , 2006, Journal of the American College of Cardiology.
[12] Salim Yusuf,et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.
[13] Fach,et al. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF) , 1999, The Lancet.
[14] M. Yacoub,et al. Molecular signature of recovery following combination left ventricular assist device (LVAD) support and pharmacologic therapy. , 2006, European heart journal.
[15] Jianbo Li,et al. The gene expression fingerprint of human heart failure , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[16] K. Shinjo,et al. Zaprinast, a well‐known cyclic guanosine monophosphate‐specific phosphodiesterase inhibitor, is an agonist for GPR35 , 2006, FEBS letters.